< Back to search
Filter
1

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for
Non-Small Cell Lung Cancer
Location: St. John's, Rimouski, Boston MA, Levis, Stony Brook NY,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06357533

Phase3, Recruiting

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

for
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type,
Location: Columbus OH
Sponsor: Lapo Alinari

Sex: All

Age: 18+

Code: NCT05755087

Phase1, Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer,
Location: Boston MA, New York NY, Fairfax VA, Pittsburgh PA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06128551

Phase1, Phase2, Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

for
Non Small Cell Lung Cancer (Squamous or Non Squamous),
Location: Mineola NY, White Plains NY, The Bronx NY, New York NY,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18+

Code: NCT07365319

Phase2, Phase3, Recruiting

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Location: Lexington KY, Houston TX, Seattle WA
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07564401

Phase1, Phase2, Recruiting

Interested in new pancreatic cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

for
Cytomegalovirus Cell Mediated Immunity,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06639854

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

for
Carcinoma, Non-Small Cell Lung
Location: Paramus NJ, Norfolk VA, Fairfax VA, Canton OH,
Sponsor: Genprex, Inc.

Sex: All

Age: 18+

Code: NCT04486833

Phase1, Phase2, Recruiting

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

for
Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05027633

Phase2, Recruiting

Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

for
Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised,
Location: Cooperstown NY, Hollywood FL, Atlanta GA, Gilbert AZ,
Sponsor: Alpha Tau Medical LTD.

Sex: All

Age: 18+

Code: NCT06615635

Recruiting

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT07603856

Phase2, Recruiting

The Minimalist Trial-2

for
HPV-Related Oropharynx Squamous Cell Carcinoma
Location: St Louis MO, Fargo ND, Sioux Falls SD
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06702033

Phase2, Recruiting

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

for
Metastatic Melanoma, Advanced Locoregional Melanoma,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05155033

Phase2, Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: The Bronx NY, Newark NJ, New Brunswick NJ, Baltimore MD,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05172245

Phase1, Recruiting

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

for
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05027945

Phase2, Recruiting

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

for
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma,
Location: Toronto, Calgary
Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 15+

Code: NCT07297667

Phase1, Recruiting

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

for
Non-small Cell Lung Cancer (NSCLC)
Location: Edison NJ, Arlington VA, Glendale CA, Los Angeles CA,
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07566052

Phase3, Recruiting

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

for
Large B-cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06045247

Phase2, Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Moncton, Sherbrooke, Albany NY, Greenfield Park,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05947851

Phase3, Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

for
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC),
Location: Athens GA, Knoxville TN, Huntsville AL, Hinsdale IL,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07489066

Phase2, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: Halifax, Shirley NY, New York NY, Albany NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase3, Recruiting